Request Demo
Last update 23 Apr 2026
SAR-445399
Last update 23 Apr 2026
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms SAR 445399, SAR445399 |
Target |
Action inhibitors |
Mechanism IL1RAP inhibitors(Interleukin-1 receptor accessory protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 1228963532H
Source: *****
Sequence Code 1228963537L
Source: *****
Related
2
Clinical Trials associated with SAR-445399NCT07225569
A Randomized, Double-blind, Placebo-controlled, Phase 2, Dose-finding Study to Investigate the Efficacy and Safety of SAR445399 in Participants With Moderate to Severe Hidradenitis Suppurativa
CTIS2024-511241-19-00
A study to investigate immune challenge induced skin reactions with SAR445399, canakinumab and spesolimab compared with placebo, in healthy participants aged 18 to 55 years
100 Clinical Results associated with SAR-445399
Login to view more data
100 Translational Medicine associated with SAR-445399
Login to view more data
100 Patents (Medical) associated with SAR-445399
Login to view more data
100 Deals associated with SAR-445399
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hidradenitis Suppurativa | Phase 2 | United States | 29 Dec 2025 | |
| Hidradenitis Suppurativa | Phase 2 | China | 29 Dec 2025 | |
| Hidradenitis Suppurativa | Phase 2 | Japan | 29 Dec 2025 | |
| Hidradenitis Suppurativa | Phase 2 | Argentina | 29 Dec 2025 | |
| Hidradenitis Suppurativa | Phase 2 | Belgium | 29 Dec 2025 | |
| Hidradenitis Suppurativa | Phase 2 | Canada | 29 Dec 2025 | |
| Hidradenitis Suppurativa | Phase 2 | France | 29 Dec 2025 | |
| Hidradenitis Suppurativa | Phase 2 | Germany | 29 Dec 2025 | |
| Hidradenitis Suppurativa | Phase 2 | Hungary | 29 Dec 2025 | |
| Hidradenitis Suppurativa | Phase 2 | Italy | 29 Dec 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free